New serological biomarkers of inflammatory bowel disease |
| |
Authors: | Li Xuhang Conklin Laurie Alex Philip |
| |
Affiliation: | 1. Division of Gastro-enterology,Department of Medicine,Johns Hopkins University School of Medicine,Baltimore MD 21205,United States 2. Division of Gastro-enterology,Department of Medicine,Johns Hopkins University School of Medicine,Baltimore MD 21205,United States;Division of Gastroenterology and Nutrition,Department of Pediatrics,Johns Hopkins Univerity School of Medicine,Baltimore MD 21205,United States |
| |
Abstract: | Serological biomarkers in inflammatory bowel disease (IBD) are a rapidly expanding list of non-invasive tests for objective assessments of disease activity, early diagnosis, prognosis evaluation and surveillance. This review summarizes both old and new biomarkers in IBD, but focuses on the development and characterization of new serological biomarkers (identified since 2007). These include five new anti-glycan antibodies, anti-chitobioside IgA (ACCA), anti-laminaribioside IgG (ALCA), anti-manobioside IgG (AMCA), and antibodies against chemically synthesized ( summation operator) two major oligomannose epitopes, Man alpha-1,3 Man alpha-1,2 Man ( summation operatorMan3) and Man alpha-1,3 Man alpha-1,2 Man alpha-1,2 Man ( summation operatorMan4). These new biomarkers serve as valuable complementary tools to existing biomarkers not only in differentiating Crohn's disease (CD), ulcerative colitis (UC), normal and other non-IBD gut diseases, but also in predicting disease involvement (ileum vs colon), IBD risk (as subclinical biomarkers), and disease course (risk of complication and surgery). Interestingly, the prevalence of the antiglycan antibodies, including anti-Saccharomyces cerevisiae antibodies (ASCA), ALCA and AMCA, was found to be associated with single nucleotide polymorphisms (SNPs) of IBD susceptible genes such as NOD2/CARD15, NOD1/CARD4, toll-like receptors (TLR) 2 and 4, and beta-defensin-1. Furthermore, a gene dosage effect was observed: anti-glycan positivity became more frequent as the number of NOD2/CARD15 SNPS increased. Other new serum/plasma IBD biomarkers reviewed include ubiquitination factor E4A (UBE4A), CXCL16 (a chemokine), resistin, and apolipoprotein A-IV. This review also discusses the most recent studies in IBD biomarker discovery by the application of new technologies such as proteomics, fourier transform near-infrared spectroscopy, and multiplex enzyme-linked immunosorbent assay (ELISA) 's (with an emphasis on cytokine/chemokine profiling). Finally, the prospects of developing more clinically useful novel diagnostic algorithms by incorporating new technologies in serological biomarker profiling and integrating multiple biomarkers with bioinformatics analysis/modeling are also discussed. |
| |
Keywords: | Serological biomarkers Inflammatory bowel disease Ulcerative colitis Crohn's disease Anti-chitobioside IgA Anti-laminaribioside IgG Anti-manobioside IgG Anti-synthetic mannoside antibodies Multiplex enzyme-linked immunosorbent assay Proteomics |
本文献已被 维普 万方数据 PubMed 等数据库收录! |
|